|
 Gene description for MRC2 |
| Gene name |
mannose receptor, C type 2 |
| Gene symbol |
MRC2 |
| Other names/aliases |
CD280
CLEC13E
ENDO180
UPARAP |
| Species |
Homo sapiens |
| Database cross references - MRC2 |
| ExoCarta |
ExoCarta_9902 |
| Entrez Gene |
9902 |
| HGNC |
16875 |
| MIM |
612264 |
| UniProt |
Q9UBG0
|
| MRC2 identified in exosomes derived from the following tissue/cell type |
|
Mesenchymal stem cells
|
Unpublished / Not applicable
|
|
Prostate cancer cells
|
25844599
|
| Gene ontology annotations for MRC2 |
|
|
| Experiment description of studies that identified MRC2 in exosomes |
| 1 |
| Experiment ID |
126 |
| ISEV standards |
|
✘
|
EV Biophysical techniques |
|
✔
GAPDH
|
EV Cytosolic markers |
|
✘
|
EV Membrane markers |
|
✘
|
EV Negative markers |
|
✘
|
EV Particle analysis
|
|
| Identified molecule |
protein
|
| Identification method |
Mass spectrometry [LTQ-FT Ultra]
|
| PubMed ID |
Unpublished / Not applicable
|
| Organism |
Homo sapiens |
| Experiment description |
Mesenchymal Stem Cell Exosomes: The Future MSC-based Therapy? |
| Authors |
Ruenn Chai Lai, Ronne Wee Yeh Yeo, Soon Sim Tan, Bin Zhang, Yijun Yin, Newman Siu Kwan Sze, Andre Choo, and Sai Kiang Lim |
| Journal name |
Mesenchymal Stem Cell Therapy
|
| Publication year |
2011 |
| Sample |
Mesenchymal stem cells |
| Sample name |
huES9.E1 |
| Isolation/purification methods |
HPLC |
| Flotation density |
-
|
| Molecules identified in the study |
Protein |
| Methods used in the study |
Western blotting
Antobody array
Mass spectrometry |
|
|
| 2 |
| Experiment ID |
275 |
| ISEV standards |
|
✔
EM
|
EV Biophysical techniques |
|
✔
TSG101|Alix|RAB5A
|
EV Cytosolic markers |
|
✔
CD9|CD82|CD63|CD81
|
EV Membrane markers |
|
✔
AIF
|
EV Negative markers |
|
✔
NTA
|
EV Particle analysis
|
|
| Identified molecule |
protein
|
| Identification method |
Mass spectrometry
|
| PubMed ID |
25844599
|
| Organism |
Homo sapiens |
| Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
| Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
| Journal name |
Oncotarget
|
| Publication year |
2015 |
| Sample |
Prostate cancer cells |
| Sample name |
DU145 - Docetaxel sensitive |
| Isolation/purification methods |
Filtration
Ultracentrifugation
Sucrose density gradient |
| Flotation density |
1.12-1.19 g/mL
|
| Molecules identified in the study |
Protein |
| Methods used in the study |
Mass spectrometry/Flow cytometry/Western blotting |
|
|
| Protein-protein interactions for MRC2 |
| |
Protein Interactor |
ExoCarta ID |
Identification method |
PubMed |
Species |
|
No interactions are found.
|
|
| Pathways in which MRC2 is involved |
|
|
|
